Thuc-Nguyen Tran, DO
Adult Medicine · Carrollton, TXNPI 1114995305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 29.5% of the total.
Across 116 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$663
- Novo Nordisk$364
- Boehringer Ingelheim$328
- Lilly USA, LLC$161
- GSK$146
- Abbott$109
- plus $474 from 16 others
What the payments were for
- Food & beverage$2,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $663 |
| Novo Nordisk | 19 | $364 |
| Boehringer Ingelheim | 18 | $328 |
| Lilly USA, LLC | 9 | $161 |
| GSK | 10 | $146 |
| Abbott | 4 | $109 |
| Pfizer | 6 | $93 |
| Merck | 4 | $70 |
| Exact Sciences | 2 | $43 |
| Dexcom, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 1 | $30 |
| Phadia US Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Biotronik NRO, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,246 in reported general payments places this provider in the 75th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 13 | $1,553 |
| Rosuvastatin Calcium | 61 | $1,060 |
| Sertraline Hcl | 13 | $553 |
| Omeprazole | 29 | $517 |
| Amlodipine Besylate | 56 | $380 |
| Atorvastatin Calcium | 56 | $349 |
| Metoprolol Succinate | 32 | $326 |
| Losartan Potassium | 34 | $318 |
| Levothyroxine Sodium | 37 | $260 |
| Alendronate Sodium | 28 | $198 |
| Montelukast Sodium | 14 | $163 |
| Metformin Hcl ErMetformin Hcl | 28 | $125 |
| Lisinopril | 25 | $112 |
| Valsartan | 11 | $103 |
| Carvedilol | 16 | $102 |
Paid to pharmacies, not to this prescriber.
Other adult medicine in Carrollton
- Hong XiaoCarrollton$10K
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
- Jeffory ThomasTexarkana$8K
- Manuel SanchezMcAllen$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.